244 related articles for article (PubMed ID: 26201283)
1. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
[TBL] [Abstract][Full Text] [Related]
2. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.
Schnaiter A; Paschka P; Rossi M; Zenz T; Bühler A; Winkler D; Cazzola M; Döhner K; Edelmann J; Mertens D; Kless S; Mack S; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2013 Aug; 122(7):1266-70. PubMed ID: 23821658
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
4. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
[TBL] [Abstract][Full Text] [Related]
6. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
7. An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.
Cortelezzi A; Gritti G; Laurenti L; Cuneo A; Ciolli S; Di Renzo N; Musto P; Mauro FR; Cascavilla N; Falchi L; Zallio F; Callea V; Maura F; Martinelli S; Piciocchi A; Reda G; Foà R;
Br J Haematol; 2012 Feb; 156(4):481-9. PubMed ID: 22150204
[TBL] [Abstract][Full Text] [Related]
8. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
9. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
10. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
11. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
[TBL] [Abstract][Full Text] [Related]
12. Short telomere length is associated with NOTCH1/SF3B1/TP53 aberrations and poor outcome in newly diagnosed chronic lymphocytic leukemia patients.
Mansouri L; Grabowski P; Degerman S; Svenson U; Gunnarsson R; Cahill N; Smedby KE; Geisler C; Juliusson G; Roos G; Rosenquist R
Am J Hematol; 2013 Aug; 88(8):647-51. PubMed ID: 23620080
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Oscier DG; Rose-Zerilli MJ; Winkelmann N; Gonzalez de Castro D; Gomez B; Forster J; Parker H; Parker A; Gardiner A; Collins A; Else M; Cross NC; Catovsky D; Strefford JC
Blood; 2013 Jan; 121(3):468-75. PubMed ID: 23086750
[TBL] [Abstract][Full Text] [Related]
14. Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Gritti G; Reda G; Maura F; Piciocchi A; Baldini L; Molica S; Neri A; Cortelezzi A
Leuk Lymphoma; 2012 Mar; 53(3):424-9. PubMed ID: 21919823
[TBL] [Abstract][Full Text] [Related]
15. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Rossi D; Bruscaggin A; Spina V; Rasi S; Khiabanian H; Messina M; Fangazio M; Vaisitti T; Monti S; Chiaretti S; Guarini A; Del Giudice I; Cerri M; Cresta S; Deambrogi C; Gargiulo E; Gattei V; Forconi F; Bertoni F; Deaglio S; Rabadan R; Pasqualucci L; Foà R; Dalla-Favera R; Gaidano G
Blood; 2011 Dec; 118(26):6904-8. PubMed ID: 22039264
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
[TBL] [Abstract][Full Text] [Related]
17. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.
Fiegl M; Erdel M; Tinhofer I; Brychtova Y; Panovska A; Doubek M; Eigenberger K; Fonatsch C; Hopfinger G; Mühlberger H; Zabernigg A; Falkner F; Gastl G; Mayer J; Greil R;
Ann Oncol; 2010 Dec; 21(12):2410-2419. PubMed ID: 20466745
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.
Fiegl M; Stauder R; Steurer M; Mian M; Hopfinger G; Brychtova Y; Skrabs C; Zabernigg A; Schmid F; Haslbaur F; Winder G; Walder A; Lang A; Voskova D; Greil R; Mayer J; Gastl G;
Ann Hematol; 2014 Feb; 93(2):267-77. PubMed ID: 24292560
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
